Company Overview and News
Chicago, IL – August 21, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Amazon.com (AMZN - Free Report) , Petroleo Brazileiro S.A (PBR - Free Report) , Gilead Sciences (GILD - Free Report) and KLA-Tencor (KLAC - Free Report) .
VRTX GILD FIX RDN MDR JOUT KLAC CCBG AMZN BSTC MLNX ADM MCDFF NSIT
All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.
Researchers are divided on wafer fab equipment spending this year with Gartner projecting a 6% increase followed by cyclical correction in 2019 and 2020 after which the market is expected to return to growth. SEMI however sees 11.7% growth this year to $50.8 billion, with the front end growing stronger than the back-end.
LRCX ASML AMAT KLAC
Wall Street’s bullish wave, which commenced in July, continues in the first week of August despite the presence of trade war concerns and geopolitical conflicts. The benchmark S&P 500 index — generally used by market participants as the barometer of the broad market movement — was up for fifth straight week. Robust U.S. economy, strong labor market, solid consumer and business spending along with government’s deregulation policies is likely to pave the way for further upside.
RHI BIIB BGSF FUN KLAC
2018-08-06 seekingalpha - 1
This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages in each industry.
GLW AMD CAIAF CA QCOM KLAC
WallStars show positive broker target price upsides. Top "safer" dividend Technology WallStar, Western Digital, showed 51.55% gains. Top ten averaged 27% per Broker estimates plus dividends. All leaders signaled oversold.
WSO LRCX WDC STX TEL KLAC AMAT AVGO DTST CSCO QCOM INTC MXIM
Some dividend stocks pay a very appealing yield — but at what price? Some of the classic dividend stocks look pretty weak from an investing perspective. For example, Exxon Mobil (NYSE:XOM) has a very cautious Hold analyst consensus. So does General Electric (NYSE:GE) and Procter & Gamble (NYSE:PG). If you are going down the dividend route, you may as well find stocks which are performing well, regardless of the dividend — stocks where the price is set to rise.
SIX GE GEC PG GILD XOM CVX GNE VLO KLAC
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
The following slide deck was published by KLA-Tencor Corporation in conjunction with their 2018 Q4 earnings call.
KLA-Tencor Corporation (KLAC - Free Report) reported fourth-quarter fiscal 2018 earnings of $2.22 per share, beating the Zacks Consensus Estimate by 8 cents. The figure surged 36% from the year-ago quarter and 10% sequentially.
GRPN ALGN ORBK WYNN IDTI EMES KLAC
Good afternoon. My name is Lance and I will be your conference operator today. At this time, I would like to welcome everyone to the KLA-Tencor Corporation Fourth Quarter Fiscal Year 2018 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. Mr. Ed Lockwood of KLA-Tencor Investor Relations, you may begin your conference.
KLA-Tencor (KLAC - Free Report) just came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $2.14 per share. This compares to earnings of $1.64 per share a year ago. These figures are adjusted for non-recurring items.
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
as of ET